Overview

Activated Protein C in Acute Stroke Trial

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to determine the safety and learn more about the dose of Activated Protein C (APC) in reducing the damage from stroke.

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Drotrecogin alfa activated
Protein C